Amarin's Vascepa shows OS benefit in colorectal cancer trial
Tweet Send to a Friend
Amarin Corporation (NASDAQ: AMRN) reported results from the Phase 3 EPA for Metastasis Trial 2 (EMT2), a University of Leeds-sponsored ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




